Stock Track | Relay Therapeutics Plummets 8.60% Despite Beating Q2 Estimates as Raymond James Slashes Target Price

Stock Track

Aug 08

Relay Therapeutics (NASDAQ: RLAY) saw its stock price plummet 8.60% in pre-market trading on Friday, despite reporting better-than-expected second-quarter results. The sharp decline appears to be largely driven by a significant target price cut from a major analyst firm.

The biotechnology company reported a quarterly adjusted loss of $0.41 per share for the quarter ended June 30, beating the mean analyst estimate of a $0.49 loss. Revenue came in at $677,000, substantially surpassing expectations of $60,000. This marks the fourth consecutive quarter that Relay Therapeutics has exceeded analyst projections.

However, the positive earnings surprise was overshadowed by Raymond James's decision to slash its target price for Relay Therapeutics from $29 to $19. This substantial 34% reduction in the expected value of the company likely spooked investors, triggering the sell-off. Despite the cut, the new target price still represents a significant upside from the stock's last closing price of $3.49, indicating that Raymond James maintains a relatively optimistic long-term outlook for the company despite near-term challenges.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1123193898"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1123193898\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1123193898?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-08 21:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1123193898","market":"us","top_or_hot":-1,"title":"Stock Track | Relay Therapeutics Plummets 8.60% Despite Beating Q2 Estimates as Raymond James Slashes Target Price","media":"Stock Track","content":"<p>Relay Therapeutics (NASDAQ: RLAY) saw its stock price plummet 8.60% in pre-market trading on Friday, despite reporting better-than-expected second-quarter results. The sharp decline appears to be largely driven by a significant target price cut from a major analyst firm.</p>\n\n<p>The biotechnology company reported a quarterly adjusted loss of $0.41 per share for the quarter ended June 30, beating the mean analyst estimate of a $0.49 loss. Revenue came in at $677,000, substantially surpassing expectations of $60,000. This marks the fourth consecutive quarter that Relay Therapeutics has exceeded analyst projections.</p>\n\n<p>However, the positive earnings surprise was overshadowed by Raymond James's decision to slash its target price for Relay Therapeutics from $29 to $19. This substantial 34% reduction in the expected value of the company likely spooked investors, triggering the sell-off. Despite the cut, the new target price still represents a significant upside from the stock's last closing price of $3.49, indicating that Raymond James maintains a relatively optimistic long-term outlook for the company despite near-term challenges.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Relay Therapeutics Plummets 8.60% Despite Beating Q2 Estimates as Raymond James Slashes Target Price</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Relay Therapeutics Plummets 8.60% Despite Beating Q2 Estimates as Raymond James Slashes Target Price\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-08-08 21:39</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Relay Therapeutics (NASDAQ: RLAY) saw its stock price plummet 8.60% in pre-market trading on Friday, despite reporting better-than-expected second-quarter results. The sharp decline appears to be largely driven by a significant target price cut from a major analyst firm.</p>\n\n<p>The biotechnology company reported a quarterly adjusted loss of $0.41 per share for the quarter ended June 30, beating the mean analyst estimate of a $0.49 loss. Revenue came in at $677,000, substantially surpassing expectations of $60,000. This marks the fourth consecutive quarter that Relay Therapeutics has exceeded analyst projections.</p>\n\n<p>However, the positive earnings surprise was overshadowed by Raymond James's decision to slash its target price for Relay Therapeutics from $29 to $19. This substantial 34% reduction in the expected value of the company likely spooked investors, triggering the sell-off. Despite the cut, the new target price still represents a significant upside from the stock's last closing price of $3.49, indicating that Raymond James maintains a relatively optimistic long-term outlook for the company despite near-term challenges.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RLAY","symbol_name":"Relay Therapeutics","start_time":0,"source_url":"","article_id":"1123193898","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1123193898","pubTimestamp":1754660363,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Relay Therapeutics (NASDAQ: RLAY) saw its stock price plummet 8.60% in pre-market trading on Friday, despite reporting better-than-expected second-quarter results. The sharp decline appears to be...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"RLAY":"Relay Therapeutics"},"translate_title":"个股追踪|Relay Therapeutics暴跌8.60%，尽管Q2超出预期，雷蒙德·詹姆斯(Raymond James)大幅下调目标价","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RLAY":1},"content_text":"Relay Therapeutics (NASDAQ: RLAY) saw its stock price plummet 8.60% in pre-market trading on Friday, despite reporting better-than-expected second-quarter results. The sharp decline appears to be largely driven by a significant target price cut from a major analyst firm.\nThe biotechnology company reported a quarterly adjusted loss of $0.41 per share for the quarter ended June 30, beating the mean analyst estimate of a $0.49 loss. Revenue came in at $677,000, substantially surpassing expectations of $60,000. This marks the fourth consecutive quarter that Relay Therapeutics has exceeded analyst projections.\nHowever, the positive earnings surprise was overshadowed by Raymond James's decision to slash its target price for Relay Therapeutics from $29 to $19. This substantial 34% reduction in the expected value of the company likely spooked investors, triggering the sell-off. Despite the cut, the new target price still represents a significant upside from the stock's last closing price of $3.49, indicating that Raymond James maintains a relatively optimistic long-term outlook for the company despite near-term challenges.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}